Advanced Chemical Industries (ACI) PLC, one of Bangladesh’s leading conglomerates, has successfully transitioned back to profitability during the first half of the 2025-26 fiscal year (July–December). The turnaround was driven by a robust double-digit growth in revenue, according to the company’s unaudited financial statements for the second quarter (October–December).
Financial Turnaround: From Loss to Profit
The company reported a consolidated revenue of Tk 7,794 crore for the July–December period, marking a 17.74% increase compared to Tk 6,620 crore in the same period of the previous year.
This growth in top-line earnings allowed ACI to post a net profit after tax of Tk 30.20 crore. This is a significant recovery from the Tk 64.60 crore net loss incurred during the same period in the 2024-25 fiscal year.
Key Half-Year Performance Indicators:
-
Earnings Per Share (EPS): Tk 0.73 (Up from a loss of Tk 7.99 per share)
-
Net Asset Value Per Share (NAVPS): Tk 90.70 (As of December 31, 2025)
-
Revenue Growth: 17.74% YoY
Previous Year Performance and Dividends
The financial recovery follows a challenging 2024-25 fiscal year. Despite reporting a consolidated loss per share of Tk 7.40 for that year, ACI’s board recommended a 25% cash dividend for its investors. The loss in FY2024-25 was, however, an improvement over the Tk 18.25 loss per share recorded in FY2023-24.
For the 2023-24 fiscal year, the company had distributed a total of 35% dividend, comprising 20% cash and 15% stock.
Company Profile and Shareholding
Listed on the stock market since 1976, ACI PLC operates with an authorized capital of Tk 300 crore and a paid-up capital of Tk 87.83 crore. As of late 2025, the company maintains a reserve of Tk 591.65 crore.
Shareholding Structure (as of Dec 31, 2025):
| Stakeholder Category | Ownership Percentage |
| Sponsor Directors | 46.84% |
| Institutional Investors | 34.43% |
| General Investors | 18.73% |
With a total of 87,831,843 shares, the company remains a heavyweight in the Dhaka Stock Exchange, covering sectors ranging from pharmaceuticals and consumer brands to agribusiness and retail.
